These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32981939)

  • 21. Adjusting for treatment selection in phase II/III clinical trials with time to event data.
    Khan JN; Kimani PK; Glimm E; Stallard N
    Stat Med; 2023 Jan; 42(2):146-163. PubMed ID: 36419206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parameter estimation following an adaptive treatment selection trial design.
    Luo X; Wu SS; Xiong J
    Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.
    Mai W; Chow SC
    J Biopharm Stat; 2024 Mar; ():1-14. PubMed ID: 38515269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.
    Gajewski BJ; Statland J; Barohn R
    Stat Biopharm Res; 2019; 11(4):375-386. PubMed ID: 31839873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II.
    Pepić A; Stark M; Friede T; Kopp-Schneider A; Calderazzo S; Reichert M; Wolf M; Wirth U; Schopf S; Zapf A
    Stat Methods Med Res; 2024 Mar; 33(3):433-448. PubMed ID: 38327081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.
    Palermos D; Sergentanis TN; Gavriatopoulou M; Malandrakis P; Psaltopoulou T; Terpos E; Ntanasis-Stathopoulos I
    J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interval estimation in multi-stage drop-the-losers designs.
    Lu X; He Y; Wu SS
    Stat Methods Med Res; 2018 Jan; 27(1):221-233. PubMed ID: 26980742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive Clinical Trials: Overview of Phase III Designs and Challenges.
    Maca J; Dragalin V; Gallo P
    Ther Innov Regul Sci; 2014 Jan; 48(1):31-40. PubMed ID: 30231417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance.
    Roychoudhury S; Scheuer N; Neuenschwander B
    Clin Trials; 2018 Oct; 15(5):452-461. PubMed ID: 30204025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.